Trial Profile
Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms ASAPIII
- Sponsors Viela Bio
- 09 Nov 2021 Results from two RCTs ASAP-III and TRACTISS trials in Patients with Primary Sjogren's Syndrome presented at the ACR Convergence 2021
- 06 Jun 2020 Results of open- label extension presented at the 21st Annual Congress of the European League Against Rheumatism
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.